Altamira Therapeutics Holds Annual Shareholder Meeting
Ticker: CYTOF · Form: 6-K · Filed: Jun 11, 2025 · CIK: 1601936
| Field | Detail |
|---|---|
| Company | Altamira Therapeutics LTD. (CYTOF) |
| Form Type | 6-K |
| Filed Date | Jun 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: agm, corporate-event, filing
TL;DR
Altamira Therapeutics had its shareholder meeting on June 11, 2025. No details on what happened.
AI Summary
Altamira Therapeutics Ltd. held its Annual General Meeting of Shareholders on June 11, 2025. The filing does not specify the outcomes or resolutions from this meeting, only that it occurred. The company was formerly known as Auris Medical Holding Ltd. and Auris Medical Holding AG.
Why It Matters
This filing confirms the occurrence of the annual shareholder meeting, a routine corporate event. The lack of specific details on resolutions or outcomes leaves investors without immediate insight into company decisions.
Risk Assessment
Risk Level: low — This is a routine filing confirming a shareholder meeting, with no new financial or operational information that would immediately impact risk.
Key Players & Entities
- Altamira Therapeutics Ltd. (company) — Registrant
- Auris Medical Holding Ltd. (company) — Former Company Name
- Auris Medical Holding AG (company) — Former Company Name
- June 11, 2025 (date) — Date of Annual General Meeting
FAQ
When was Altamira Therapeutics Ltd.'s Annual General Meeting of Shareholders held?
The Annual General Meeting of Shareholders was held on June 11, 2025.
What was Altamira Therapeutics Ltd. previously named?
Altamira Therapeutics Ltd. was formerly known as Auris Medical Holding Ltd. and Auris Medical Holding AG.
Does this filing provide details on the resolutions passed at the AGM?
No, this filing confirms the meeting took place but does not specify the resolutions or outcomes.
What is the principal executive office address for Altamira Therapeutics Ltd.?
The principal executive office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda.
Under which SEC Act is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 11, 2025 regarding Altamira Therapeutics Ltd. (CYTOF).